Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Common Equity of -$337.0 million for Q1 2026, little changed year-over-year from -$335.5 million in Q1 2025, and up 23.1% quarter-over-quarter from -$438.2 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Common Equity data on file, last reported at -$337.0 million in Q1 2026.
- Common Equity for Q1 2026 came in at -$337.0 million, changed 0.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$337.0 million (changed 0.42% YoY), and the FY2025 annual result was -$438.2 million, down 72.79% from the prior year.
- Common Equity rose to -$337.0 million in Q1 2026 per PHAT's latest filing, from -$438.2 million in the prior quarter.
- Over five years, Common Equity peaked at $38.0 million in Q1 2022 and troughed at -$438.2 million in Q4 2025.
- A 5-year average of -$176.4 million and a median of -$148.5 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity jumped 351.43% in 2023, then plunged 1428.57% in 2024.
- A 5-year view of Common Equity shows it stood at -$74.8 million in 2022, then grew by 2.75% to -$72.8 million in 2023, then plunged by 248.52% to -$253.6 million in 2024, then slumped by 72.79% to -$438.2 million in 2025, then increased by 23.1% to -$337.0 million in 2026.
- Business Quant data shows PHAT's Common Equity at -$337.0 million in Q1 2026, -$438.2 million in Q4 2025, and -$422.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -336.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -336.96 Mn |
| Dec 31, 2025 | -438.17 Mn |
| Sep 30, 2025 | -422.53 Mn |
| Jun 30, 2025 | -405.83 Mn |
| Mar 31, 2025 | -338.38 Mn |
| Dec 31, 2024 | -253.58 Mn |
| Sep 30, 2024 | -187.11 Mn |
| Jun 30, 2024 | -233.83 Mn |
| Mar 31, 2024 | -148.50 Mn |
| Dec 31, 2023 | -72.76 Mn |
| Sep 30, 2023 | -17.77 Mn |
| Jun 30, 2023 | 17.60 Mn |
| Mar 31, 2023 | -90.20 Mn |
| Dec 31, 2022 | -74.81 Mn |
| Sep 30, 2022 | -26.42 Mn |
| Jun 30, 2022 | -7.00 Mn |
| Mar 31, 2022 | 38.04 Mn |
| Dec 31, 2021 | 72.16 Mn |
| Sep 30, 2021 | 103.48 Mn |
| Jun 30, 2021 | 132.13 Mn |